Login to Your Account



Voltarra seeks 'lightning' strike with zoledronic acid derivative in knee OA

By Marie Powers
Staff Writer

Wednesday, May 21, 2014
Launched last year with a portfolio of early stage small molecules and late-stage clinical assets assembled through a pair of acquisitions, Voltarra Pharmaceuticals Inc. has moved like lightning – a strategy underpinning the company's name – into phase III trials for its lead candidate.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription